Werewolf Therapeutics, Inc.

NASDAQ: HOWL · Healthcare · Biotechnology

PublicHQ Watertown, MA · MiddlesexCIK 0001785530Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 30DQ —GM —SS 40

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, market scale · ↓ return on equity, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$60.8M

Employees

as of 2026-08-21

Market cap

$21.0M

as of 2026-08-21

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$60.8M-$60.8M2025

Operating income-$60.7M-$60.7M2025

Total assets$69.4M$69.4M2025

Liabilities$44.6M$44.6M2025

Equity$24.8M$24.8M2025

Revenue by segment

Filed disclosures · FY2024

By product

Reportable100%

By geography

Not disclosed.

The read

What is Werewolf Therapeutics, Inc.’s financial profile?

Werewolf Therapeutics, Inc. earned -$60.8M in FY2025 net income.

Peers · Healthcare

Actuate Therapeutics Inc——NurExone Biologic Inc.——Quantum BioPharma Ltd.——Cellectar Biosciences, Inc.——ProMIS Neurosciences, Inc.——ImpediMed Limited——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B49D

Key facts

CEODaniel J. Hicklin

SectorHealthcare

IndustryBiotechnology

HeadquartersWatertown, MA

ExchangeNASDAQ: HOWL

Employees39

IPO date2021-04-30

Latest filings

8-K2026-05-07 10-Q2026-05-07 10-K2026-03-27 8-K2026-03-27 8-K2026-02-24 8-K2026-02-13 8-K2026-02-06 8-K2025-12-18

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.